Sona Nanotech Inc. (CSE:SONA)

Verve Therapeutics Income Statement

Financials in millions CAD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 30, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020
Selling, General & Admin	1.51	1.56	1.63	1.74	2.41	2.42
Research & Development	0.43	0.19	0.23	-0.25	-0.04	0.37
Operating Expenses	3.08	2.84	2.61	3.02	10.67	5.95
Operating Income	-3.08	-2.84	-2.61	-3.02	-10.67	-5.95
Interest Expense	-0.04	-0.05	-0.07	-0.08	-0.02	-0.03
Currency Exchange Gain (Loss)	-0	0	-0.01	-0.01	0.04	-
Other Non Operating Income (Expenses)	-	-	-	0.17	-	-
EBT Excluding Unusual Items	-3.12	-2.88	-2.69	-2.94	-10.65	-5.98
Gain (Loss) on Sale of Investments	-0	-0	-0	-0	0.01	0
Gain (Loss) on Sale of Assets	-	-	0.04	-	-	-
Other Unusual Items	0.18	0.18	0.15	0.58	0.28	-0.3
Pretax Income	-2.94	-2.7	-2.5	-2.36	-10.37	-6.27
Net Income	-2.94	-2.7	-2.5	-2.36	-10.37	-6.27
Net Income to Common	-2.94	-2.7	-2.5	-2.36	-10.37	-6.27
Shares Outstanding (Basic)	107	101	86	68	64	60
Shares Outstanding (Diluted)	107	101	86	68	64	60
Shares Change (YoY)	10.61%	17.22%	25.35%	6.80%	6.43%	9.93%
EPS (Basic)	-0.03	-0.03	-0.03	-0.03	-0.16	-0.10
EPS (Diluted)	-0.03	-0.03	-0.03	-0.03	-0.16	-0.10
Free Cash Flow	-2.35	-1.96	-1.26	-1.81	-3.81	-4.43
Free Cash Flow Per Share	-0.02	-0.02	-0.01	-0.03	-0.06	-0.07
EBITDA	-2.36	-2.11	-2.15	-2.96	-10.6	-5.89
D&A For EBITDA	0.72	0.73	0.46	0.06	0.07	0.07
EBIT	-3.08	-2.84	-2.61	-3.02	-10.67	-5.95

Source: S&P Global Market Intelligence. Standard template. Financial Sources.